Carregant...
Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study
BACKGROUND: The phase III COntinuous or INtermittent (COIN) trial failed to demonstrate a benefit in overall survival of cetuximab in combination with chemotherapy for patients with metastatic colorectal cancer (mCRC). High derived neutrophil to lymphocyte ratio (dNLR) has been shown to be prognosti...
Guardat en:
| Publicat a: | Anticancer Drugs |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5390854/ https://ncbi.nlm.nih.gov/pubmed/28252533 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CAD.0000000000000488 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|